Bio-Thera Launches Adalimumab In China
Qletli Biosimilar Is First Chinese Humira Rival
Bio-Thera Solutions has launched its first product in China, with its Qletli adalimumab biosimilar representing the first Humira rival to be approved under the country’s biosimilars pathway and just the second biosimilar approved overall.
You may also be interested in...
China’s Bio-Thera Solutions has revealed the details of its latest clinical trials for proposed biosimilar rivals to Cosentyx (secukinumab) and Nucala (mepolizumab).
Shanghai Junshi and Mabwell have received approval from China’s NMPA for their co-developed adalimumab biosimilar rival to Humira.
Bio-Thera has joined the ranks of biosimilars developers that have rivals to Stelara in Phase III trials, after kicking off a study for its BAT2206 proposed version of ustekinumab.